

DBV Technologies to Host and Webcast Investor Day in New York City on May 21, 2014

BAGNEUX, France, May 12, 2014 - DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of food allergies, today announced that a live webcast of its Investor Day scheduled for Wednesday, May 21st will be available on the Company's website, www.dbv-technologies.com, on the Investor Relations section. The presentation will begin at 8:30 AM Eastern Time (or 2:30 PM CET) at the Le Parker Meridien Hotel in New York, NY.

DBV Technologies' senior management will review the Company's Epicutaneous Immunotherapy (EPIT™) method, its pipeline strategy and its proprietary Viaskin® technology. DBV will also provide an update on its ongoing international Phase IIb, VIPES, in peanut allergic patients with Viaskin® Peanut and present its global development plan. Key food allergy opinion leaders will also present during the event. Key Opinion Leaders will also discuss the place of EPIT in the world of allergies. Presenters include:

- Professor Franklin Adkinson: Professor of Medicine at Johns Hopkins Asthma and Allergy Center;
- Dr. Gordon Sussman: Division Head of University of Toronto Clinical Immunology and Allergy and investigator for DBV's VIPES study;
- Professor Jonathan Spergel: Chief of the Allergy Department and co-Director of the Center for Pediatric Eosinophilic
 Disorders at the Children's Hospital of Philadelphia;
- Professor Christophe Dupont: Head of the Pediatrics-Gastroenterology Department at the Necker Hospital in Paris and Principal Investigator for Arachild study.


Investors and Analyst wishing to attend the investor day in New-York City on May 21st are requested to RSVP at the following e-mail address: <u>tjames@troutgroup.com.com</u> or <u>susanna.mesa@dbv-technologies.com</u>.

About DBV Technologies

DBV Technologies is opening up a decisive new approach to the treatment of allergy — a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company's significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy — a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).

CAUTION: Viaskin® is not approved for sale in the USA.





DBV Technologies Contacts

David Schilansky

Chief Financial Officer Tel.: +33(0)1 55 42 78 75

david.schilansky@dbv-technologies.com

Susanna Mesa

VP Finance, US Investor Relations & Strategy

Tel.: +1 917-346-3447

susanna.mesa@dbv-technologies.com

Nathalie Donne

Director, Business Development & Corporate Communications

Tel.: +33(0)1 55 42 78 72

nathalie.donne@dbv-technologies.com

DBV IR and Media Contacts

Todd James

U.S. Investor Relations The Trout Group Tel.: +1 646-378-2926

tjames@troutgroup.com

BMC Communications

Media Relations Brad Miles

Tel.: +1 646-513-3125

brad@bmccommunications.com